Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

The prognostic value of tumour-infiltrating lymphocytes (TILs) differs by breast cancer (BC) subtype. The aim of this study was to evaluate TILs in stage III BC in the context of BRCA1/2-like phenotypes and association with outcome and benefit of intensified platinum-based chemotherapy. Patients participated in a randomised controlled trial of adjuvant intensified platinum-based chemotherapy versus conventional anthracycline-based chemotherapy carried out between 1993 and 1999 in stage III BC. Stromal TILs were scored according to International guidelines in these human epidermal growth factor receptor 2 (HER2)-negative tumours. BRCA-profiles were determined using Comparative Genomic Hybridization. TIL levels were evaluated in 248 BCs. High TILs were associated with Triple Negative BC (TNBC). BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01). TIL levels in BRCA1-like tumours were higher compared to BRCA2-like tumours (median TILs of 20% versus 10%, p < 0.001). These correlations remained significant within the oestrogen (ER)-positive subgroup, however not within the TNBC subgroup. In this stage III BC cohort, high TIL level was associated with favourable outcome (TILs per 10% increment, recurrence-free survival (RFS): multivariate hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71-0.94, p = 0.01; overall survival (OS): multivariate HR 0.80, 95% CI 0.68-0.94, p = 0.01). There was no significant interaction between TILs and benefit of intensified platinum-based chemotherapy. In this high-risk breast cancer cohort, high TILs were associated with TNBC and BRCA1-like status. Within the ER-positive subgroup, TIL levels were higher in BRCA1-like compared to BRCA2-like tumours. When adjusted for clinical characteristics, TILs were significantly associated with a more favourable outcome in stage III BC patients.

de Boo L ，Cimino-Mathews A ，Lubeck Y ，Daletzakis A ，Opdam M ，Sanders J ，Hooijberg E ，van Rossum A ，Loncova Z ，Rieder D ，Trajanoski Z ，Vollebergh M ，Sobral-Leite M ，van de Vijver K ，Broeks A ，van der Wiel R ，van Tinteren H ，Linn S ，Horlings HM ，Kok M ... -  《-》

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.

Vollebergh MA ，Lips EH ，Nederlof PM ，Wessels LF ，Wesseling J ，Vd Vijver MJ ，de Vries EG ，van Tinteren H ，Jonkers J ，Hauptmann M ，Rodenhuis S ，Linn SC ... -  《-》

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.

Kolberg-Liedtke C ，Gluz O ，Heinisch F ，Feuerhake F ，Kreipe H ，Clemens M ，Nuding B ，Malter W ，Reimer T ，Wuerstlein R ，Graeser M ，Shak S ，Nitz U ，Kates R ，Christgen M ，Harbeck N ... -  《-》

Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.

Gao ZH ，Li CX ，Liu M ，Jiang JY ... -  《BMC CANCER》

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.

Lips EH ，Benard-Slagter A ，Opdam M ，Scheerman CE ，Wesseling J ，Hogervorst FBL ，Linn SC ，Savola S ，Nederlof PM ... -  《-》